-
enGene completes LEGEND trial enrollment with 62% response rate, reports FY results
-
H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)
-
enGene selected for FDA manufacturing pilot program
-
Engene Holdings Inc. (ENGN) PT Raised to $33 at Oppenheimer
-
Engene Holdings (ENGN) PT Raised to $21 at Citizens on Detalimogene Safety Profile
-
Engene Holdings Inc. (ENGN) PT Raised to $21 at Leerink Partners
-
Raymond James Upgrades Engene Holdings Inc. (ENGN) to Strong Buy
-
enGene reports 62% response rate for bladder cancer treatment
-
H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)
-
H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)
-
enGene completes enrollment of 100 patients in bladder cancer trial
-
enGene adds three board members and promotes executives for commercialization
-
Engene (ENGN): FDA Grants RMAT Designation for Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
-
H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)
-
Citizens JMP Reiterates Market Outperform Rating on Engene Holdings Inc. (ENGN)
-
Raymond James Reiterates Outperform Rating on Engene Holdings Inc. (ENGN)
-
Engene (ENGN) announces CMO resignation
-
Engene (ENGN) Appoints Amy Pott as Chief Global Commercialization Officer
-
Citizens JMP Reiterates Market Outperform Rating on Engene Holdings Inc. (ENGN)
-
H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)
-
Engene (ENGN) Tops Q1 EPS by 48c
-
Piper Sandler Starts Engene Holdings Inc. (ENGN) at Overweight
-
7 top biotech picks for 2025 according to Wells Fargo
-
H.C. Wainwright Starts Engene Holdings Inc. (ENGN) at Buy
-
JMP Securities Starts Engene Holdings Inc. (ENGN) at Market Outperform
-
Engene (ENGN) Announces $60 Million Private Placement Financing
-
Engene (ENGN) Appoints Joan Connolly as CTO, Anthony Cheung as Chief Scientific Officer
-
Oppenheimer Reiterates Outperform Rating on Engene Holdings Inc. (ENGN)
-
Engene Holdings Inc. (ENGN) PT Lowered to $17 at Leerink Partners
-
Morgan Stanley Reiterates Overweight Rating on Engene Holdings Inc. (ENGN)
-
Oppenheimer Reiterates Outperform Rating on Engene Holdings Inc. (ENGN)
-
Oppenheimer Starts Engene Holdings Inc. (ENGN) at Outperform
-
Engene (ENGN) Appoints Ron Cooper as CEO
-
NewAmsterdam Pharma (NAMS) Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

